Concomitant ixekizumab and tirzepatide improved skin clearance and reductions in weight in patients with moderate-to-severe psoriasis

Risankizumab was associated with a lower risk of serious infections when compared to other systemic treatments for psoriasis

Sensitive skin syndrome is biologically distinct from rosacea and may require more targeted treatment.